Is flunarizine a long-acting oral atypical antipsychotic? A randomized clinical trial versus haloperidol for the treatment of schizophrenia

Journal of Clinical Psychiatry

Volumn 69, Issue 10, 2008, Pages 1572-1579

  Bisol, Luísa W ^a   Brunstein, Miriam G ^b   Ottoni, Gustavo L ^a   Ramos, Fernanda L P ^b   Borba, Daniela L ^c   Daltio, Claudiane S ^d   De Oliveira, Ricardo V ^a   Paz, Gisele E G ^c   De Souza, Sayuri E ^d   Bressan, Rodrigo A ^d   Lara, Diogo R ^c  

^a FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^b HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

^c PONTIFICAL CATHOLIC UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^d FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

FLUNARIZINE; HALOPERIDOL;

ABSENCE OF SIDE EFFECTS; ADULT; AGGRESSION; AGITATION; AKATHISIA; ANXIETY; ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL; COGNITION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DECREASED APPETITE; DISEASE EXACERBATION; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSKINESIA; DYSTONIA; FEMALE; HEADACHE; HUMAN; INCREASED APPETITE; INSOMNIA; LABORATORY TEST; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PARKINSONISM; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SIDE EFFECT; SOMNOLENCE; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; WEIGHT GAIN;

EID: 54949130166     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v69n1007     Document Type: Article

References (40)

1. Seeman P, Lee T. Antipsychotic drugs: direct correlation between clinical potency and presynaptic action on dopamine neurons. Science 1975;188:1217-1219
2. Johnstone EC, Crow TJ, Frith CD, et al. Mechanism of the antipsychotic effect in the treatment of acute schizophrenia. Lancet 1978;1:848-851
3. 2 receptors, yet occupy high levels of these receptors. Mol Psychiatry 1998;3:123-134
4. Miyamoto S, Duncan GE, Marx CE, et al. Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs. Mol Psychiatry 2005;10:79-104
5. Leone M, Grazzi L, La Mantia L, et al. Flunarizine in migraine: a minireview. Headache 1991;31:388-391
6. Schmidt R, Oestreich W. Flunarizine in the treatment of vestibular vertigo: experimental and clinical data. J Cardiovasc Pharmacol 1991;18(suppl 8):S27-S30
7. Agnoli A, Manna V, Martucci N, et al. Randomized double-blind study of flunarizine versus placebo in patients with chronic cerebrovascular disorders. Int J Clin Pharmacol Res 1988;8:189-197
8. Todd PA, Benfield P. Flunarizine: a reappraisal of its pharmacological properties and therapeutic use in neurological disorders. Drugs 1989;38:481-499
9. Chouza C, Scaramelli A, Caamano JL, et al. Parkinsonism, tardive dyskinesia, akathisia, and depression induced by flunarizine. Lancet 1986;1:1303-1304
10. Brücke T, Wober C, Podreka I, et al. D2 receptor blockade by flunarizine and cinnarizine explains extrapyramidal side effects: a SPECT study. J Cereb Blood Flow Metab 1995;15:513-518
11. 2 and D1 receptors. Eur J Pharmacol 1991;197:221-223
12. Haraguchi K, Ito K, Kotaki H, et al. Catalepsy induced by calcium channel blockers in mice. Biopharm Drug Dispos 1998;19:115-122
13. 2 occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia. Am J Psychiatry 2000;157:514-520
14. Holmes B, Brogden RN, Heel RC, et al. Flunarizine: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic use. Drugs 1984;27:6-44
15. Grebb JA. Nifedipine and flunarizine block amphetamine-induced behavioral stimulation in mice. Life Sci 1986;38:2375-2381
16. Rosenzweig-Lipson S, Barrett JE. Modification of the behavioral effects of (+/-) BAY k 8644, cocaine and d-amphetamine by L-type calcium channel blockers in squirrel monkeys. J Pharmacol Exp Ther 1995;274:842-851
17. Hori Y, Takeda H, Tsuji M, et al. Differentiation of the inhibitory effects of calcium antagonists on abnormal behaviors induced by methamphetamine or phencyclidine. Pharmacology 1998;56:165-174
18. Tort AB, Dall'Igna OP, de Oliveira RV, et al. Atypical antipsychotic profile of flunarizine in animal models. Psychopharmacology (Berl) 2005;177:344-348
19. Corbett R, Camacho F, Woods AT, et al. Antipsychotic agents antagonize noncompetitive N-methyl-D-aspartate antagonist-induced behaviors. Psychopharmacology (Berl) 1995;120:67-74
20. Popoli P, Pezzola A, Benedetti M, et al. Verapamil and flunarizine inhibit phencyclidine-induced effects: an EEG and behavioural study in rats. Neuropharmacology 1992;31:1185-1191
21. Feinberg I, Campbell IG. Haloperidol potentiates the EEG slowing of MK-801 despite blocking its motor effects: implications for the PCP model of schizophrenia. Neuroreport 1998;9:2189-2193
22. Pledger GW, Sackellares JC, Treiman DM, et al. Flunarizine for treatment of partial seizures: results of a concentration-controlled trial. Neurology 1994;44:1830-1836
23. Volavka J, Czobor P, Sheitman B, et al. Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder. Am J Psychiatry 2002;159:255-262
24. Bilder RM, Goldman RS, Volavka J, et al. Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder. Am J Psychiatry 2002;159:1018-1028
25. 2 receptors and sensitivity to endogenous dopamine. Br J Psychiatry 2002;180:465-466
26. 2 receptor occupancy in patients with recent-onset schizophrenia treated with low-dose olanzapine or haloperidol: a randomized, double-blind study. Am J Psychiatry 2003;160:303-309
27. Lindelius R, Nilsson CG. Flunarizine as maintenance treatment of a patient with bipolar disorder [letter]. Am J Psychiatry 1992;149:139
28. Eckmann F. Clinical double blind study with the calcium antagonist flunarizine cerebral circulatory disturbances [in German]. Arzneimittelforschung 1985;35:1276-1279
29. Teive HA, Troiano AR, Germiniani FM, et al. Flunarizine and cinnarizine-induced parkinsonism: a historical and clinical analysis. Parkinsonism Relat Disord 2004;10:243-245
30. Kariya S, Isozaki S, Masubuchi Y, et al. Possible pharmacokinetic and pharmacodynamic factors affecting parkinsonism inducement by cinnarizine and flunarizine. Biochem Pharmacol 1995;50:1645-1650
31. Belfiore G, Di Maio L, Napolitano G, et al. Long-term effect of a single dose of flunarizine in Huntington's disease. Eur J Neurol 1998;5:249-253
32. Poignet H, Beaughard M, Lecoin G, et al. Functional, behavioral, and histological changes induced by transient global cerebral ischemia in rats: effects of cinnarizine and flunarizine. J Cereb Blood Flow Metab 1989;9:646-654
33. Berger R, Lehmann T, Karcher J, et al. Low dose flunarizine protects the fetal brain from ischemic injury in sheep. Pediatr Res 1998;44:277-282
34. Tong JX, Rich KM. Diphenylpiperazines enhance regeneration after facial nerve injury. J Neurocytol 1997;26:339-347
35. Patro IK, Chattopadhyay M, Patro N. Flunarizine enhances functional recovery following sciatic nerve crush lesion in rats. Neurosci Lett 1999;263:97-100
36. Dispersyn G, Nuydens R, Borgers M, et al. Nimodipine and flunarizine have different effects on survival and morphology of PC12 cells during nerve growth factor deprivation. Eur J Pharmacol 1999;384:61-70
37. Kaminski-Schierle GS, Hansson O, Brundin P. Flunarizine improves the survival of grafted dopaminergic neurons. Neuroscience 1999;94:17-20
38. Popoli P, Pezzola A, Scotti de Carolis A. Possible involvement of the adenosinergic system in flunarizine anticonvulsant activity in rats. Arch Int Pharmacodyn Ther 1990;306:45-56
39. Heinze B, Karrass W, Peters T. Pharmacopsychological effects of flunarizine in geriatric patients with light brain organic psychosyndrome: preliminary communication. Eur Neurol 1986;25:115-121
40. Jeste DV, Palmer BW, Harris MJ. Neuroleptic discontinuation in clinical and research settings: scientific issues and ethical dilemmas. Biol Psychiatry 1999;46:1050-1059